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Conclusions: The target volume coverage and the normal tissue doses 
in patients with prostate cancer were compared between the 3 
treatment plans, using VERO, TomoTherapy, and Clinac 21EX. The 
similar acceptable dose delivery can be achieved in all 3 treatment 
plans. In clinical use, treatment time and image-guided accuracy may 
be the other issues to be considered for higher precision radiotherapy.  
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Purpose/Objective: On-board cone beam CT (CBCT) makes it possible 
to adaptively modify the patient's treatment plan with consideration 
of organ deformation and delivered doses. The CBCT images from the 
Elekta Synergy system have shown large deviations in CT number and, 
as are sult, an elaborate correction strategy is required. In this study, 
for direct dose recomputation on the CBCT images, we were 
developed multi-region histograms methods and investigated the 
potential impact of an integrated procedure for CBCT-based adaptive 
prostate IMRT treatment. 
Materials and Methods: Incase of ten prostate IMRT treatment, 
patient anatomy (prostate, rectum,bladder, etc.) were outlined using 
simulation CT (sim-CT, GE Optima CT 660Pro). Over the treatment 
course of each patient, the CBCT were acquired using ELECTA Synergy 
prior to treatment. The CBCTs were registered to the sim-CTusing a 
deformable algorism and patient anatomy outlined on the sim-CT was 
auto/manual-mapped to the CBCTs (Velocity AI). Then, the HU-D 
table for CBCT was generated by the relative electron densities using 
our methods (in-house program). The cumulative and delivered dose 
of CBCTs obtained using the patient treatment plan. To assess 
adaptive approach for IMRT, the dose delivery history of patient 
anatomy reconstructed after each CBCT was used to analyze 
statistically the confidence interval.  
Results: The max dose, D99 and D95 of cumulative dose for the 
prostate, the proximal and the distal seminal vesicles were small 
difference about ± 2.0%. It is possible that the difference of the 
middle cumulative dose could be more than 2%, but the ?nal 
cumulative dose is still within 2%. The R65 and R40 of the rectum 
were large difference more than 17.0%, 10.0%, respectively. 
Moreover, the B65 andB40 of the bladder were large difference about 
10.0%, 20.0%, respectively. The differences between the cumulative 
and initial plan doses for the OARs were different for each case. The 
PTV margin is commonly used to account for the a geographic miss. In 
this study, with the PTV margins used in current prostate IMRT, the 
dose to the rectum and bladder were large difference while 
maintaining target coverage.Therefore, if the integrated procedure 
methods of the adaptive prostate IMRT treatment of image guidance 
and evaluation of dose using the CBCT are appropriate, the PTV 
margin might be to eliminate. Thereby, the dose to the rectum and 
bladder might be reduced. Moreover, our study suggested that 
correcting the patient's daily setup is often not enough for the OARs 
because of organs deformation. Therefore, accounting for the organ 
deformation is important, especially if the target margin is to be 
reduced for dose escalation. 
Conclusions: Adaptive therapy based on the volumetric on-board CT 
imaging and patient treatment history is an effective way to deliver 
highly conformal IMRT dose to prostate patients on a routine basis. 
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Purpose/Objective: Helical tomotherapy (HT) has been recommended 
as a suitable radiotherapy procedure for breast cancer patients with 
involvement of the supraclavicular nodes (Goddu et al. 2009, Ashenafi 
et al. 2010). The spillover of low doses on non-target organs may 
represents a high risk factor for secondary cancer induction and thus 
the biggest limitation in tomotherapy. Recently, TomoDirect (TD), a 
tomotherapy mode using discrete delivery angles, has been proposed 
as a valid alternative to the helical approach (Jones et. al 2012), 
because it reduces the doses released to the organs at risk (OARs) and 
improves the irradiation treatment time. The reduction in the number 
of fields for tomodirect improves the control of low doses. The 
present work aimed to evaluate the benefits of TD versus HT. 
Materials and Methods: Four cases were selected as representative 
for right or left target as for thin or thick breast shapes. Each case 
was separately planned using helical and direct modalities, prescribing 
50 Gy delivered in 25 fractions to the PTVs. All plans were optimized 
with 2.5 cm jaws and pitch of 0.25 for TD and 0.287 for HT. TD 
planning was performed by selecting 7 fixed fields: 2 tangential fields 
on the breast (PTV1) and 5 fields on the mammary nodes (PTV2). For 
each TD plan the beamlet entrance to the controlateral breast was 
blocked and a dummy organ in the junction area was defined to 
reduce the hotspots and to control the local dose. Dose homogeneity 
was evaluated by the uniformity index (UI) of D5/D95. Comparison 
between direct and helical planning was performed by the evaluation 
of dose volume histogram parameters for PTVs, ipsilateral and 
contralateral lung, contralateral breast and heart, as shown in Table 
1.  
Results: All the organs received doses well below the tolerance levels 
and the PTV coverage and UI resulted equivalent in both the 
approaches (Table 1). High target dose homogeneity was achieved 
with TD on both PTV1 (1.07) and PTV2 (1.03). A significant reduction 
(p<0.05) was observed in the volumes receiving low doses in ipsilateral 
lung (V5(%) decreased from 53.4% in HT to 25.3% in TD, V10(%) from 
29.2% in HT to 17.6% in TD), heart (V5(%) from 71.1% in HT to 4.8% in 
TD) and body (V5(%) from 31.5% in HT to 15.7% in TD). A significant 
increase was found in the volumes with high doses in the ipsilateral 
lung (V40(%) raised from 0.5% in HT to 3.8% in TD), while no significant 
differences were observed for the remaining parameters investigated. 
Treatment duration time in HT (11.9 ± 1.2 min) was comparable with 
TD (11.3 ± 2.2 min). 
 
 
Conclusions: When compared to HT, TD can provide a significant 
reduction of low doses for heart, ipsilateral lung and body, with 
equivalent high homogeneity target coverage. Further, it ensures a 
complete PTV1 irradiation by opening 3 leafs in the air for the 
tangential fields, avoiding target missing for respiratory motion.  
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Purpose/Objective: To validate the 'mid-position' approach for lung 
tumor motion management in helical tomotherapy with 4D Monte 
Carlo planning simulation, in comparison with conventional ITV. 
Materials and Methods: 8 patients with stage I non-small cell lung 
cancer (NSCLC) treated by SBRT were included, as well as 6 patients 
with stage II-III NSCLC treated by Simultaneous Integrated Boost (SIB) 
and participating in a dose escalation protocol. Prior to treatment, a 
contrast-enhanced CT (CE-CT) and a 4DCT (for SBRT) or a combined 
4D FDG-PET-CT (for SIB) were acquired. The GTV, CTV, and OARs were 
delineated on the CE-CT according to our clinical protocol. Next, 4D 
data were used to generate first the ITV and then the MidP volume in 
its exact time-weighted mean position of the respiratory motion, using 
a validated Morphon non-rigid registration algorithm. The PTVs were 
finally drawn according to the margin formula for geometric 
uncertainties developed by Van Herk et al. and adapted to the 
specific features of lung tumor tomotherapy. For each patient, two 
treatments were planned based on margins derived from the ITV and 
MidP volume. Volumetric and dosimetric parameters, as well as 
conformity indexes were compared with both strategies. Moreover, 
dose distributions were computed using a 4D Monte Carlo (MC) model, 
in order to assess the impact of intra-fraction tumor motion on tumor 
coverage (quantified by D95), with and without the interplay effect. 
Results: For SBRT and SIB patients, the PTVs defined with the ITV 
approach were on average 1.2 times larger than those derived from 
MidP. Consequently, the dose to all the OARs was on average lower 
when using the MidP. Nonetheless, the planned dose conformity to 
TVs was identical between both strategies (0,92 ± 0,03 and 0,84 ± 
0,05 for DICE and Paddick indexes, respectively). For all SBRT 
patients, D95 to the GTV computed from 4D MC dose distributions 
complied within 1% of the planning recommendations when using the 
ITV approach. In contrast, MidP failed to ensure adequate GTV 
coverage in 3 patients. For one patient, the simulated interplay effect 
lowered the D95 to the GTV by 4.35% compared to the planned dose 
distribution (Fig a). Although the interplay effect did not affect the 
two other patients, simulated MC calculations demonstrated 
significant GTV underdosages, with D95 to GTV reduced by 2.16% and 
2.61% compared to the planned doses (Fig b). 4D MC computations are 
ongoing for the SIB group. 
 
  
Conclusions: Compared to the ITV, the MidP strategy significantly 
reduced the PTV and irradiated volumes in all patients. However, if 
MidP could safely be applied in helical tomotherapy in most cases, it 
might lead to insufficient tumor coverage for very small tumors (< 
5cc) with large motion (> 10mm). Those particular cases are indeed 
questioning the fundamental hypothesis underlying the framework of 
the MidP concept. As SIB treatments are usually delivered to large and 
centrally located tumors, MidP might allow for a safe reduction of the 
PTVs and irradiated tissues, although this still needs to be further 
confirmed.  
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Purpose/Objective: The megavoltage cone beam computed 
tomography (MV-CBCT) dose may be considered in the treatment plan 
prescription dose specially for daily image guided radiation therapy 
(IGRT) treatments. The dosimetric differences on target volumes and 
organs at risks obtained optimizing the intensity modulated treatment 
plan (IMRT) with and without the MV-CBCT were investigated for 
clinical cases routinely treated. 
Materials and Methods: A Siemens Medical Solutions, an Artiste™ 
linear accelerators mounting a MV-CBCT device implemented in Philips 
Pinnacle3 Treatment Planning System (TPS) was used for this work. 
Two different type of treatment (head and neck and prostate) 
performed with daily IGRT-IMRT techniques were enrolled. Twenty 
prostate carcinomas and twelve head and neck tumors treatment 
planning were investigated. For each clinical case the dose 
distribution and the DVH due to IMRT alone (TP1), IMRT plus MV-CBCT 
dose (TP2), IMRT optimized including MV-CBCT dose (TP3) were 
examined. Dmean and Dmax were used for target volume comparison and 
dose volume histograms (DVHs) cut off points for organs at risks 
(OARs) comparison. The impact of the MV-CBCT protocol used on the 
integral dose defined as V5Gy was investigated. The CBCT dose 
calculated was assessed with ionization chamber measurements. 
Results: The theoretical treatment plan (TP1) compared with the one 
optimized with the MV CBCT dose (TP3) did not present difference on 
target dose coverage, while if compared with TP2 (treatment plan 
added with MV CBCT dose) a mean increase of 4,1% and 3% were 
obtained for Dmean and Dmax for ORL and prostate treatment 
respectively. The OARs sparing was worsened in both comparison also 
if a better sparing is obtained with TP2. For the parotides glands the 
Dmean percent difference ranged between +8% and 16 % and for the 
V40Gy of the rectum the percent difference was between 1.5 to 8%. 
The comparison between the 8 monitor units (MU) CBCT protocol 
routinely used and the 5 MU and 15 MU protocols showed and 
increased of the V5GY integral dose between 10 to 52 % and 20 to 66% 
for ORL and prostate treatment respectively. The decreased of V5GY 
integral dose obtained with the 5M CBCT protocol ranged between -2 
to –7% for for ORL and between -6 to –13% for prostate cases. 
Conclusions: Prostate and ORL treated with IMRT and IGRT techniques 
may not be performed without the use of the daily CBCT; it is 
therefore essential to integrate the MV-CBCT dose in the patient 
prescription.  
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Purpose/Objective: VMAT is a complex, arc-based treatment 
technique for intensity modulated radiation therapy. For different 
treatment planning systems it has been shown that plan quality is 
comparable to fixed field IMRT. But achieving acceptable plan quality 
is often based on experience of the operator. This analysis compares 
the plan quality of template-based VMAT plans without operator 
interference against fixed field IMRT plans for Elekta linacs using the 
Varian TPS Eclipse on a statistical basis for various main tumour 
regions. 
Materials and Methods: 181 cases were selected for this study 
including 40 cervical and endometrial, 73 head and neck, 12 brain, 11 
breast and 45 prostate cancer cases. The IMRT plans were developed 
in clinical routine over the last three years using Eclipse TPS. VMAT 
plans were generated using a preclinical version of the Eclipse TPS 
including a VMAT optimizer for Elekta linacs. To standardize the 
optimizing process, tumour region specific optimizing templates were 
created. Based on these templates two VMAT plans were generated 
without interference of the operator: with one full arc (1A) and with 
two full arcs (2A), resp. one or two partial arcs for breast cancer 
cases. All plans were evaluated by target coverage, homogeneity and 
conformity; the organs at risk (OAR) were analysed according to plan 
objectives such as mean and maximum doses. If one or more 
objectives were exceeded, a second VMAT plan was created by 
adapting the optimizing constraints once. All evaluation parameters 
were averaged over all patients for each region and compared using 
the Wilcoxon matched-pair signed rank test. 
Results: For template-based 2A plans in 27 cases out of 181 an 
exceeding of the objectives for one or more OAR was found, in 13 
cases an over- or under-dosage in the PTV. For 1A plans 30 cases 
showed an exceeding of the OAR objectives, 25 for the target volume 
coverage. For the additionally modified plans the OAR exceeding was 
reduced to 23 cases for both 2A and 1A; the over- or under-dosage in 
the PTV was reduced to 8 cases for 2A and to 17 for 1A. In comparison 
to the IMRT plans the 1A and 2A plans showed good results concerning 
the target coverage. Small differences between the considered 
techniques can be found which depends on the tumour region. A 
similar behaviour was found for the OAR. But here, the differences 
between the different techniques and tumour regions show a wider 
